Cediranib
Ductal Breast Carcinoma In Situ
Northwestern UniversitySmall moleculePhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Ductal Breast Carcinoma In Situ cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxybutynin Academic and Community Cancer Research United | Phase 3 | BB |
Z/E 4-HYDROXY TAMOXIFEN Northwestern University | Phase 2 | B |
Docosahexaenoic Acid National Cancer Institute (NCI) | Phase 2 | B |
ESTROGENS, CONJUGATED Northwestern University | Phase 2 | B |
Bazedoxifene Northwestern University | Phase 2 | B |
Telapristone Acetate Northwestern University | Phase 2 | B |
AE-BROCCOLI Roswell Park Cancer Institute | Early Phase 1 | CC |
Lapatinib National Cancer Institute (NCI) | N/A | D |
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →